Study: No difference in results by race with standard heart failure treatment

A traditional treatment for heart failure appears to be equally protective in preventing death or hospitalization among African-American patients, as compared to white patients, according to a study at Henry Ford Hospital in Detroit.

Angiotensin converting enzyme inhibitors (ACE) and angiotensin (ARB) are standard treatments. However, they have been shown to be less effective for in African Americans when compared to white patients, and most heart failure studies have enrolled a low proportion of African Americans.

"Although previous data have been somewhat conflicting regarding the consistency of benefits of ACE/ARB across races, this study showed that the results were virtually the same for African-American compared to white patients." says Henry Ford researcher and cardiologist David Lanfear, M.D., lead author of the study.

The results will be presented May 9 at the American Heart Association's annual Quality of Care and Outcomes Research meeting (QCOR12) in Atlanta.

The retrospective study looked at insured patients who were hospitalized for heart failure at Henry Ford Hospital between January 2000 and June 2008, and who primarily received care through the Henry Ford Medical Group.

Using pharmacy claims data, the researchers were able to see the dosage and patients' adherence in filling prescriptions, and could therefore estimate the exposure to medications over time, as well as test the connection to the patients' outcomes. ACE/ARB exposure was estimated over six-month rolling periods.

A total of 1,094 patients (476 White and 618 African-Americans) were studied. The average time of follow-up was two years.

Results were adjusted for other important factors, such as gender, age, other diseases and medications (including beta blockers), in order to identify the effect specifically attributable to taking ACE/ARB medications. Data was analyzed and sorted by race.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Results of RIBS IV trial reported

11 hours ago

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided superior late angiographic results ...

Results of DKCRUSH-VI trial reported

11 hours ago

A new study found that fractional flow reserve (FFR)-guided provisional side branch (SB) stenting of true coronary bifurcation lesions yields similar outcomes to the current standard of care. The DKCRUSH-VI clinical trial ...

Results of IVUS-CTO trial reported at TCT 2014

12 hours ago

A new study found that intravascular ultrasound (IVUS) -guided intervention in patients with chronic total occlusion (CTO) could improve outcomes compared to a conventional angiography-guided approach during percutaneous ...

Results of OCT STEMI trial reported at TCT 2014

12 hours ago

The first randomized trial to examine serial optical coherence tomography (OCT) in primary percutaneous coronary intervention (PCI) was reported at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific ...

INR variability predicts warfarin adverse effects

17 hours ago

(HealthDay)—Unstable anticoagulation predicts warfarin adverse effects regardless of time in therapeutic range, according to a study published online Sept. 2 in Circulation: Cardiovascular Quality and Ou ...

User comments